ArticleJBMR plus2025
A retrospective analysis of the prevalence of hypophosphatemia and hypocalcemia after intravenous iron polymaltose in the inpatient setting.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypophosphatemia across the lifespan.JBMR plus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypophosphatemia occurring after ferric carboxymaltose or iron polymaltose infusion is common and has been well-characterized. Post-iron infusion hypocalcemia has been documented in case reports, but there is no data on the prevalence of hypocalcemia developing after i.v. iron infusion. In this retrospective cohort study, we sought to characterize integrated daily changes in serum phosphate and corrected calcium levels before and after iron infusion in a real-world inpatient setting. Inpatients who received i.v. iron polymaltose at the Royal Brisbane and Women's Hospital (Queensland, Australia) between January 2020 and September 2021 were included. We extracted all results for serum phosphate and corrected calcium levels for 21 d before and after iron infusion. A total of 741 patients with 8272 blood samples were included. The serum phosphate concentration reduced by an average of 30.6% (95% CI 28.2-32.9) in the 5 d following infusion. Serum phosphate reached a nadir at day 5 before incrementing, but still remained below baseline by the end of the study period. Conversely, serum corrected calcium levels increased within 1 d of iron polymaltose infusion and then dropped over the following 5 d. There was a significant increase in the prevalence of hypophosphatemia developing after iron polymaltose infusion (34% post-infusion vs 8% pre-infusion,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.